Citadel Advisors
VBIO

Citadel Advisors’s Valion Bio VBIO Stock Holding History

Citadel Advisors’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5K Buy
+2,966
New +$64.5K ﹤0.01% 13237
2024
Q3 		– Sell
-34
Closed -$5.63K – 15248
2024
Q2 		$5.63K Buy
+34
New +$10.7K ﹤0.01% 13384
2023
Q4 		– Sell
-39
Closed -$28.9K – 15261
2023
Q3 		$28.9K Buy
+39
New +$72.1K ﹤0.01% 12302

Other funds holding VBIO

M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's VBIO Position: Q2 2026 in Review

Citadel Advisors opened a new position in Valion Bio (VBIO) in Q2 2026: 2,966 shares worth $38.5K. The stake represents ﹤0.01% of the portfolio and ranks #13237 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in VBIO as recently as Q2 2024.

Citadel Advisors first reported a position in VBIO in Q3 2023 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold VBIO as of Q2 2026.

  • Citadel Advisors held 2,966 shares of Valion Bio worth $38.5K as of Q2 2026.
  • Valion Bio was a new Citadel Advisors position in Q2 2026.
  • Valion Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13237 holding.
  • Citadel Advisors first reported a position in Valion Bio in Q3 2023 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held Valion Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.